The recombinant respiratory syncytial virus (RSV) vaccine Arexvy (GSK) has now received FDA approval for use in adults 50-59 years old who are at increased risk for lower respiratory tract disease (LRTD) caused by RSV. It was previously approved only for adults ≥60 years old.1 Two other RSV vaccines have received FDA approval: Abrysvo, a recombinant vaccine that is licensed for use in adults ≥60 years old and in pregnant women at 32-36 weeks' gestation to prevent RSV-associated LRTD in their infants,1 and mResvia, an mRNA vaccine recently licensed for use in...  Continue reading

Coming Soon
Sofpironium (Sofdra) for Primary Axillary Hyperhidrosis
Donanemab (Kisunla) for Alzheimer's Disease
Ensifentrine (Ohtuvayre) for COPD
Drugs for COPD